Product Images Asenapine

This is a table showing different drugs and their interaction with cytochrome P450 enzymes. The table shows the fold change and 90% CI values for Cmax, AUC when these drugs are used with other drugs that inhibit certain cytochrome P450 enzymes. Additionally, a note is added to indicate that the concomitant use of fluvoxamine with asenapine may cause an increase in asenapine exposure.*

This document provides information on the change in PK Fold Change and 90% CI for various substrates and inhibitors of CYP1A2/2C19/3A4, CYP2C19/2D6. Specifically, it includes data on the Cmax and AUC values for Paroxetine®, Imipramine, and Desipramine, and the change relative to reference. The document also notes that the administration of Asenapine may enhance the inhibitory effects of Paroxetine on its own metabolism and that Asenapine appears to be a weak inhibitor of CYP206. However, coadministration of Imipramine and Asenapine did not affect the plasma concentrations of the metabolite of Imipramine (Desipramine), which is a CYP2D6 substrate.*

This text presents data depicting the effect of intrinsic factors on Asenapine Pharmacokinetics, including renal and hepatic impairment, smoking, and ethnicity. The population description includes groups with mild, moderate, and severe renal or hepatic impairment, as well as Japanese individuals. The impact of each factor is measured through Cmax and AUC, with fold changes and confidence intervals provided. The data is presented in comparison to a reference group, which is subjects with normal renal and hepatic function in the case of impairment, and non-smokers in the case of smoking. The Japanese group is compared to Caucasians.*